These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1378 related items for PubMed ID: 24265554

  • 1. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
    Foody JM, Toth PP, Tomassini JE, Sajjan S, Ramey DR, Neff D, Tershakovec AM, Hu H, Tunceli K.
    Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
    [Abstract] [Full Text] [Related]

  • 2. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 3. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
    Toth PP, Foody JM, Tomassini JE, Sajjan SG, Ramey DR, Neff DR, Tershakovec AM, Hu XH, Tunceli K.
    J Clin Lipidol; 2014 Sep; 8(1):107-16. PubMed ID: 24528691
    [Abstract] [Full Text] [Related]

  • 4. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL, Gandhi SK, Fox KM, Stacy TA, McKenney JM.
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [Abstract] [Full Text] [Related]

  • 5. More Western hypercholesterolemic patients achieve Japan Atherosclerosis Society LDL-C goals with rosuvastatin therapy than with atorvastatin, pravastatin, or simvastatin therapy.
    Strutt K, Caplan R, Hutchison H, Dane A, Blasetto J.
    Circ J; 2004 Feb; 68(2):107-13. PubMed ID: 14745143
    [Abstract] [Full Text] [Related]

  • 6. Effects of atorvastatin 20 mg, rosuvastatin 10 mg, and atorvastatin/ezetimibe 5 mg/5 mg on lipoproteins and glucose metabolism.
    Her AY, Kim JY, Kang SM, Choi D, Jang Y, Chung N, Manabe I, Lee SH.
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):167-74. PubMed ID: 20147603
    [Abstract] [Full Text] [Related]

  • 7. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
    Strandberg TE, Feely J, Sigurdsson EL, DISCOVERY study group.
    Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
    [Abstract] [Full Text] [Related]

  • 8. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB, Abate N, Catapano AL, Ballantyne CM, Davidson MH, Smugar SS, Tershakovec AM.
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [Abstract] [Full Text] [Related]

  • 9. Incremental cholesterol reduction with ezetimibe/simvastatin, atorvastatin and rosuvastatin in UK General Practice (IN-PRACTICE): randomised controlled trial of achievement of Joint British Societies (JBS-2) cholesterol targets.
    McCormack T, Harvey P, Gaunt R, Allgar V, Chipperfield R, Robinson P, IN-PRACTICE study.
    Int J Clin Pract; 2010 Jul; 64(8):1052-61. PubMed ID: 20487050
    [Abstract] [Full Text] [Related]

  • 10. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR, Gandhi SK, Heien H, McDonough K, Nelson SP.
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [Abstract] [Full Text] [Related]

  • 11. A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in diabetic patients with symptomatic cardiovascular disease.
    Rosen JB, Jimenez JG, Pirags V, Vides H, Hanson ME, Massaad R, McPeters G, Brudi P, Triscari J.
    Diab Vasc Dis Res; 2013 May; 10(3):277-86. PubMed ID: 23288881
    [Abstract] [Full Text] [Related]

  • 12. The efficacy and safety of ezetimibe/simvastatin combination compared with intensified lipid-lowering treatment strategies in diabetic subjects with and without metabolic syndrome.
    Jimenez JG, Rosen JB, Pirags V, Massaad R, Hanson ME, Brudi P, Triscari J.
    Diabetes Obes Metab; 2013 Jun; 15(6):513-22. PubMed ID: 23279632
    [Abstract] [Full Text] [Related]

  • 13. Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
    Rosen JB, Jimenez JG, Pirags V, Vides H, Massaad R, Hanson ME, Brudi P, Triscari J.
    Lipids Health Dis; 2013 Jul 16; 12():103. PubMed ID: 23866306
    [Abstract] [Full Text] [Related]

  • 14. The efficacy of statin monotherapy uptitration versus switching to ezetimibe/simvastatin: results of the EASEGO study.
    Roeters van Lennep HW, Liem AH, Dunselman PH, Dallinga-Thie GM, Zwinderman AH, Jukema JW.
    Curr Med Res Opin; 2008 Mar 16; 24(3):685-94. PubMed ID: 18226326
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of ezetimibe added to atorvastatin versus atorvastatin uptitration or switching to rosuvastatin in patients with primary hypercholesterolemia.
    Bays HE, Averna M, Majul C, Muller-Wieland D, De Pellegrin A, Giezek H, Lee R, Lowe RS, Brudi P, Triscari J, Farnier M.
    Am J Cardiol; 2013 Dec 15; 112(12):1885-95. PubMed ID: 24063830
    [Abstract] [Full Text] [Related]

  • 16. Achievement of LDL-cholesterol goal with statins after an st segment elevation myocardial infarction.
    Tungsubutra W, Phongtuntakul B.
    J Med Assoc Thai; 2015 Feb 15; 98(2):129-36. PubMed ID: 25842792
    [Abstract] [Full Text] [Related]

  • 17. Impact of Switching From High-Efficacy Lipid-Lowering Therapies to Generic Simvastatin on LDL-C Levels and LDL-C Goal Attainment Among High-Risk Primary and Secondary Prevention Populations in the United Kingdom.
    Cao X, Ejzykowicz F, Ramey DR, Sajjan S, Ambegaonkar BM, Mavros P, Tunceli K.
    Clin Ther; 2015 Apr 01; 37(4):804-15. PubMed ID: 25626487
    [Abstract] [Full Text] [Related]

  • 18. Comparison of rosuvastatin versus atorvastatin in South-Asian patients at risk of coronary heart disease (from the IRIS Trial).
    Deedwania PC, Gupta M, Stein M, Ycas J, Gold A, IRIS Study Group.
    Am J Cardiol; 2007 Jun 01; 99(11):1538-43. PubMed ID: 17531577
    [Abstract] [Full Text] [Related]

  • 19. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis.
    Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM.
    Atherosclerosis; 2014 Dec 01; 237(2):829-37. PubMed ID: 25463129
    [Abstract] [Full Text] [Related]

  • 20. Achievement rates of Japan Atherosclerosis Society Guidelines 2007 LDL-cholesterol goals with rosuvastatin or atorvastatin in patients who had not achieved their goal with atorvastatin.
    Shioji K, Izuhara M, Mitsuoka H, Uegaito T, Matsuda M, Kishiwada Atherosclerosis Prevention Study (KAPS) Group.
    Cardiovasc Ther; 2014 Jun 01; 32(3):97-104. PubMed ID: 24456217
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 69.